Are the United States stock markets open on the Fourth of July?
Here's what to know about the United States stock markets on July 4.
Yes. United States stock markets are closed on Friday, July 4, 2025. According to the New York Stock Exchange and Nasdaq websites, their markets also close early (at 1 p.m.) on Thursday, July 3.
The Federal Reserve considers the Fourth of July a bank holiday, meaning most banks will be closed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Why Krispy Kreme Was Such a Tasty Stock in June
The company was added to some of the less prominent Russell indexes. It also announced several executive transitions. 10 stocks we like better than Krispy Kreme › According to data compiled by S&P Global Market Intelligence, Krispy Kreme (NASDAQ: DNUT) stock rose a sweet 25% across the trading week shortened by the July Fourth holiday. Inclusion in several new stock indexes was the key reason why, while a set of smooth C-suite transitions put some glaze on its donut. Krispy Kreme's stock, which has been a component of the influential Russell 2000 stock index, was tapped for several other equity trackers within the same family. It's now included on the Russell 2000 Value index (not to be confused with the Russell 2000), the Russell 2500 Value index, the Russell Small Cap Comp Value index, and the Russell 3000E Value index. Although landing on an index confers prestige to a stock, such a move rarely has an impact on a company's operations and fundamentals. Still, as a component of a certain index, a stock's popularity will rise simply due to the proliferation of index funds. These instruments are limited to the stocks on a particular index, so naturally, those titles get selected for the related fund or funds. But once it becomes known that a stock is graduating to an index, this dynamic is usually priced in. Later in the week, Krispy Kreme announced a set of executive transitions. Effective July 11, it will have a new CFO -- Raphael Duvivier, its current president of international business and a long-serving company executive. He replaces Jeremiah Ashukian, who is departing for a position at an unnamed private company. Another company veteran, Alison Holder, has been promoted from her current position of chief product officer to chief brand and product officer. Previously in her 25-year career with Krispy Kreme, she filled numerous managerial roles, including senior director of consumer insights. To me, neither development is sufficient to tip Krispy Kreme into buy territory. Revenue has been flat to stagnant lately, and it's posted more quarterly net losses than profits. I don't see many growth paths for the business, especially in a world that is becoming increasingly health-conscious. Before you buy stock in Krispy Kreme, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Krispy Kreme wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Krispy Kreme Was Such a Tasty Stock in June was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Why Docusign Stock Stumbled Last Month
Its first-quarter earnings featured dynamics in one metric that worried both investors and analysts. This was despite a double beat on analyst estimates and encouraging growth in other metrics. 10 stocks we like better than Docusign › An uninspiring quarterly earnings report and a clutch of analyst price target cuts put Docusign (NASDAQ: DOCU) stock in the market's doghouse in June. The first month of summer surely wasn't the warmest for the company, as its shares lost over 12% of their value during the period. Before the first trading week of the month was over, Docusign had unveiled its first quarter of fiscal 2026 figures. At first glance, they looked good -- revenue cranked 8% higher year over year (to almost $764 million), which was an encouraging result given the company's well-established position in its niche. That was on the back of a 4% climb in billings to just under $740 million. Similarly, its bottom line rose at a pleasing rate. The company's non-GAAP (adjusted) net income improved by just over 10% to hit nearly $191 million, or $0.90 per share. Both key fundamentals easily topped the consensus analyst estimates, which called for slightly more than $749 million in revenue and per-share adjusted net income of $0.81. Meanwhile, on the stock price-supporting front, Docusign announced a $1 billion increase in its common share repurchase program, which has neither a minimum purchase commitment nor a fixed end date. As of June 5, the company added that it had $1.4 billion in potential buybacks remaining from existing authorizations. The catch with Docusign's first quarter wasn't disappointing revenue, earnings, or the bulked-up stock repurchase initiative; it was the company's billings. First, many analysts tracking the stock were expecting a higher figure than the sub-$740 million the company posted. More than one also pointed out that the actual result landed below the midpoint of management's guidance. Compounding that, Docusign cut its full-year guidance for the crucial billings figure. And while this wasn't drastic -- it's now modeling $3.28 billion to $3.34 billion, against the preceding $3.3 billion to $3.35 billion -- no investor loves it when a forecast gets the chop. At least some of the recent dynamic with billings can be attributed to product evolution. Docusign rolled out its next-generation Intelligent Agreement Management (IAM) platform in April 2024, and it seems some clients have been slow to adopt it, hence the disappointing billings performance. I feel that IAM is still relatively new. That, plus the fact that it represents a comparatively premium product from Docusign, is probably responsible for the recent drag. Yet, to me, it represents an advancement for the company, as it's offering notably more sophisticated and useful functionality for its customers. Yes, the billings performance is a concern, so if I were an investor, I'd surely watch that metric going forward. For the most part, though, I think Docusign runs a solid business, and I'd be bullish on its future. Before you buy stock in Docusign, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Docusign wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Docusign. The Motley Fool has a disclosure policy. Why Docusign Stock Stumbled Last Month was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Why Tempus AI Stock Soared 15.2% in June
Providing individualized healthcare solutions, Tempus AI is leveraging the power of AI to offer leading diagnostics and treatment options. TD Cowen's dismissal of the critical report from Spruce Point Capital Management was merely one factor contributing to Tempus AI stock's rise in June. Prospective investors who are willing to endure some volatility may still benefit from a position in Tempus AI. 10 stocks we like better than Tempus Ai › The market's appetite for artificial intelligence (AI) stocks remains unyielding, and it doesn't seem poised to wane anytime soon. Shares of Tempus AI (NASDAQ: TEM), for example, rose 7.1% in April and 6.8% in May, and continued to climb higher at a more rapid pace last month. According to data provided by S&P Global Market Intelligence, Tempus AI stock climbed 15.2% in June. In addition to a perspective on the critical report written about the company that's developing AI solutions for healthcare applications, analysts' auspicious opinions on Tempus AI stock and the company's development provided motivation for investors. Following the release of a critical report by Spruce Point Capital Management about Tempus AI in May, investors rushed to exit their positions. But the selling activity reversed course in early June when investors learned that TD Cowen was unmoved by the report. According to TD Cowen's analyst found "some of [the] stated concerns misleading or incorrect."Another catalyst for the stock's rise last month came from the company's introduction of its Fuses program. An initiative to provide even greater individualized care for patients, the Fuses program will grow the company's AI-assisted diagnostics and expand its comprehensive testing portfolio, using machine learning coupled with data from its expansive library. Bullish sentiment from Wall Street helped Tempus AI stock sustain the gains it had logged throughout the month. On June 25, an analyst from Bank of America raised the price target on Tempus AI stock to $70 from $68, and on June 30, Guggenheim raised its price target to $75 from $65. For context, Tempus AI closed at $55.18 on the last day of trading in May. With shares of Tempus AI climbing steadily over the past several months, it's reasonable for prospective investors to question whether they've missed the boat. At this point, though, it seems that this is hardly the case. Tempus AI is early in its development, and the use of AI to provide individualized healthcare is a nascent industry that will likely boom in the coming years. Naturally, Tempus AI stock will face some volatility as the company strives to overcome the hurdles that face growth companies. Those with long investing horizons, however, would be well advised to give the stock a serious look, as there certainly remains plenty of potential for the stock to soar even higher. Before you buy stock in Tempus Ai, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Tempus Ai wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Bank of America is an advertising partner of Motley Fool Money. Scott Levine has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bank of America. The Motley Fool has a disclosure policy. Why Tempus AI Stock Soared 15.2% in June was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
